Teprasiran

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Teprasiran
Accession Number
DB15064
Type
Biotech
Groups
Investigational
Description

Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).

Synonyms
Not Available
External IDs
QPI-1002
Categories
Not Available
UNII
O03W5S19PJ
CAS number
1231737-88-4

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1TerminatedPreventionAcute Kidney Injury (AKI) / Acute Renal Failure (ARF)1
1, 2CompletedPreventionDelayed Graft Function / Other Complications of Kidney Transplant1
2CompletedPreventionAcute Kidney Injury (AKI)1
3Active Not RecruitingPreventionDelayed Graft Function1
3RecruitingPreventionSurgery, Cardiac1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on May 20, 2019 08:46 / Updated on May 21, 2019 12:34